EQL Pharma AB (publ) (STO:EQL)
26.30
+1.15 (4.57%)
At close: Aug 14, 2026
EQL Pharma AB Ratios and Metrics
Market cap in millions SEK. Fiscal year is April - March.
Millions SEK. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 777 | 1,606 | 2,064 | 1,229 | 1,087 | 974 | |
Market Cap Growth | -68.75% | -22.15% | 67.85% | 13.10% | 11.64% | -2.05% |
Enterprise Value | 1,175 | 1,971 | 2,205 | 1,317 | 1,075 | 1,010 |
Last Close Price | 26.30 | 54.40 | 71.00 | 42.30 | 37.40 | 33.50 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | - | 128.12 | 47.85 | 54.15 | 35.15 | 30.86 |
Forward PE | 21.43 | 29.17 | 31.21 | 16.99 | - | - |
PS Ratio | 1.80 | 3.71 | 5.53 | 4.65 | 4.18 | 2.38 |
PB Ratio | 3.10 | 6.02 | 9.34 | 6.92 | 7.02 | 7.88 |
P/TBV Ratio | - | - | - | 42.91 | 20.82 | 38.62 |
P/FCF Ratio | 36.61 | 70.10 | - | - | 40.02 | 23.63 |
P/OCF Ratio | 36.51 | 56.64 | - | - | 39.36 | 23.28 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 2.72 | 4.56 | 5.90 | 4.99 | 4.14 | 2.47 |
EV/EBITDA Ratio | 32.89 | 29.89 | 29.38 | 33.94 | 22.70 | 24.92 |
EV/EBIT Ratio | 85.78 | 41.25 | 33.03 | 40.38 | 26.01 | 26.01 |
EV/FCF Ratio | 55.40 | 86.00 | - | - | 39.59 | 24.52 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 1.84 | 1.72 | 2.06 | 0.68 | 0.43 | 0.62 |
Debt / EBITDA Ratio | 12.86 | 6.82 | 5.93 | 2.98 | 1.37 | 1.83 |
Debt / FCF Ratio | 21.67 | 20.04 | - | - | 2.45 | 1.85 |
Net Debt / Equity Ratio | 1.59 | 1.40 | 1.69 | 0.56 | 0.14 | 0.28 |
Net Debt / EBITDA Ratio | 11.62 | 5.65 | 4.97 | 2.57 | 0.47 | 0.86 |
Net Debt / FCF Ratio | 18.79 | 16.26 | -12.13 | -8.06 | 0.82 | 0.85 |
Asset Turnover | 0.54 | 0.52 | 0.63 | 0.80 | 0.99 | 1.86 |
Inventory Turnover | 1.59 | 1.42 | 1.53 | 1.74 | 2.69 | 7.47 |
Quick Ratio | 0.83 | 0.95 | 0.97 | 0.53 | 0.83 | 0.77 |
Current Ratio | 1.83 | 1.92 | 1.81 | 1.22 | 1.43 | 1.25 |
Return on Equity (ROE) | -5.84% | 5.14% | 21.63% | 13.66% | 22.21% | 29.37% |
Return on Assets (ROA) | 1.06% | 3.60% | 7.06% | 6.18% | 9.87% | 11.00% |
Return on Invested Capital (ROIC) | 2.13% | 5.33% | 12.15% | 11.40% | 19.56% | 21.96% |
Return on Capital Employed (ROCE) | 2.20% | 7.50% | 11.40% | 15.40% | 24.50% | 27.90% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | -1.81% | 0.78% | 2.09% | 1.85% | 2.84% | 3.24% |
FCF Yield | 2.73% | 1.43% | -1.49% | -1.01% | 2.50% | 4.23% |
Buyback Yield / Dilution | 1.52% | -0.92% | -0.34% | -0.91% | -1.59% | - |